Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Renal Cell Carcinoma. Found 66 abstracts

no pagination
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. PharmacoEconomics. 2019 Mar;37(3):301-31.   PMCID: PMC6886358
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2019 Oct 09;:101097ju0000000000000588.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of Malignant and Normal Kidney Tissue with Short Wave Infra-Red Dispersive Raman Spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 Sep;2(9):1179-86.   PMCID: PMC5568541
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU international. 2015 Sep;116(3):351-7.
Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100.
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology & Therapy. 2015 May;16(5):743-9.   PMCID: 4623021
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Renal Cell Carcinoma

Renal Cell Carcinoma Kidney Neoplasms Male Middle Aged Female Aged drug therapy therapeutic use pathology administration & dosage mortality Antineoplastic Agents Disease-Free Survival Adult adverse effects surgery 80 and over Aged therapy Nephrectomy Sunitinib Survival Rate Adjuvant Chemotherapy Risk Factors Pyrroles diagnosis methods Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Retrospective Studies Indoles epidemiology secondary Neoplasm Staging Follow-Up Studies Kidney analogs & derivatives Prospective Studies genetics renal cell Proto-Oncogene Proteins c-met Oral Administration antagonists & inhibitors Double-Blind Method statistics & numerical data Sulfonamides Pyrimidines Niacinamide Phenylurea Compounds carcinoma Sorafenib Kidney cancer Cost-Benefit Analysis Local Neoplasm Recurrence economics Nivolumab tissue diagnosis Time Factors Risk Assessment Renal cell carcinoma Tumor Biomarkers Monoclonal Antibodies Signal transducer and activator of transcription STAT Intention to Treat Analysis cytoreductive nephrectomy Age Factors Ros Survival Analysis Vascular endothelial growth factor receptor VEGFR Targeted therapy Reactive Oxygen Species Disease Progression blood piperlongumine Amino acids Ribonucleic acid RNA Renal cell carcinoma RCC systemic therapy Molecular Models Patient Readmission High-Volume Hospitals Cost of Illness Mitogen-activated protein kinase MAPK Intravenous Administration Hepatocyte growth factor HGF Metastatic renal cell carcinoma Classification Raman spectroscopy Treatment patterns Pazopanib Young Adult Registries Biological Models Spectroscopy Randomized Controlled Trials as Topic etiology cytology Perioperative Period Cancer survival survival local Phase III Clinical Trials as Topic Nuclear factor kappaB NF-kB hemorrhage Prognosis Blood Transfusion Case-Control Studies Extracellular signal-regulated kinase Erk United States Tryptophan Raman nephrectomy nutritional status Tyrosine kinase inhibitors TKIs Surgical Blood Loss Dioxolanes Ipilimumab Quality of Life enzymology Histidine Drug Costs Biopsy Immunotherapy Monoclonal Antibodies-Humanized pharmacology Antiangiogenic Single-Blind Method Raman Spectrum Analysis c-Met Hypoalbuminemia standards clopidogrel Immunological Antineoplastic Agents Focal adhesion kinase FAK Signal Transduction Oral anticancer medications Programmed Cell Death 1 Receptor Axitinib Antineoplastic agents Medical Oncology Multicenter Studies as Topic Factual Databases Mice Platelet Aggregation Inhibitors Logistic Models aspirin prevention & control Low-Volume Hospitals Response Evaluation Criteria in Solid Tumors neoplasm recurrence Tumor Cell Line
Last updated on Saturday, July 04, 2020